Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
monoflurophosphate · 1 trial · 1 indication
Percent SMH recovery (SMHR) was calculated from hardness values of enamel specimens at baseline (B), after in-situ hardening (R) and after first demineralization challenge (D1) using formula: \[(D1-R)/ (D1-B)\]\*100. A greater percentage change in SMHR represents a better remineralisation and hence a better outcome.
| Arm | Type | Description |
|---|---|---|
| CSP/SMFP Dentifrice | EXPERIMENTAL | Dentifrice containing high fluoride content as SMFP and CSP |
| SMFP Dentifrice Prototype 1 | ACTIVE_COMPARATOR | Dentifrice containing high fluoride content as SMFP and no CSP |
| SMFP Dentifrice Prototype 2 | ACTIVE_COMPARATOR | Dentifrice containing low fluoride content as SMFP and no CSP |
| CSP Dentifrice | ACTIVE_COMPARATOR | Dentifrice containing CSP but no fluoride |
| Placebo Dentifrice | PLACEBO_COMPARATOR | Dentifrice containing no CSP and no fluoride |
| Name | Type | Description |
|---|---|---|
| Calcium sodium phosphosilicate | DRUG | CSP high percentage weight by weight |
| Sodium monoflurophosphate | DRUG | 500 to 1500 parts per million (ppm) of fluoride |
| Placebo | DRUG | No CSP and no fluoride |
Inclusion Criteria: * Wears a removable bilateral mandibular partial denture that has good stability and support, with sufficient room on each side in the posterior buccal flange area to accommodate two enamel specimens \[required dimensions 12 x 7 millimeters (mm)\].
Monoflurophosphate is a small molecule being studied for the prevention of caries, or tooth decay. It is formulated as a dentifrice, meaning it is intended for use in toothpaste or similar oral care products. The drug is currently in Phase 2 clinical development for this indication.
Monoflurophosphate is being developed by GSK plc, a global pharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical research on this compound for the treatment of caries.
Monoflurophosphate is in Phase 2 clinical development. It is an investigational drug and has not yet been approved for commercial use. A Phase 2 clinical trial has been completed to evaluate its anti-caries potential.
Monoflurophosphate has been studied in one clinical trial registered as NCT01657877. This Phase 2 trial, titled "Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice," was completed in the United States with 100 participants aged 18 years and older.
Yes, monoflurophosphate is also known as sodium monofluorophosphate. The clinical trial for this drug specifically evaluated a dentifrice containing sodium monofluorophosphate, which is the active ingredient being investigated for its anti-caries effects.